Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' (Investor Relations Management System) and is a detailed policy document outlining the company's principles, procedures, and responsibilities for managing investor relations. It includes sections on communication with investors, compliance with laws and regulations, investor meetings, disclosure practices, and internal controls related to investor relations. There is no financial data, earnings information, audit results, or regulatory filings presented. The document is a governance-related policy rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-25 Chinese
北京双鹭药业股份有限公司内幕信息知情人登记管理制度
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System' and is a detailed internal policy document of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines the rules, definitions, and procedures for managing insider information and insider personnel registration. It includes legal references, responsibilities, confidentiality agreements, and procedural details. There is no indication that this is a financial report, earnings release, or any form of shareholder meeting material. It is a governance-related internal control document focused on compliance with insider information regulations. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (9974 characters) and content confirm it is a full policy document, not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2025-08-25 Chinese
北京双鹭药业股份有限公司对外担保管理办法
Governance Information Classification · 95% confidence The document is titled '对外担保管理办法' which translates to 'External Guarantee Management Measures' and is a detailed internal policy document of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines the principles, procedures, risk management, disclosure requirements, and responsibilities related to the company's external guarantees. The document is a corporate governance or internal management policy rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, audit results, earnings data, or voting results. It is not a report publication announcement or a certification. It is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7081 characters) and content support this classification with high confidence.
2025-08-25 Chinese
北京双鹭药业股份有限公司董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会提名委员会工作细则' which translates to 'Board Nomination Committee Working Rules'. It details the structure, responsibilities, procedures, and rules governing the nomination committee of the board of directors. It does not contain financial data, audit information, or regulatory filings. Instead, it focuses on governance practices related to board nominations and management appointments. This fits the description of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is 2610 characters, which is sufficient for a detailed governance report rather than a brief announcement or notice.
2025-08-25 Chinese
北京双鹭药业股份有限公司董事、高级管理人员持有及买卖本公司股份的专项管理制度
Governance Information Classification · 95% confidence The document is titled as a special management system for the holding and trading of company shares by directors and senior management of Beijing Shuanglu Pharmaceutical Co., Ltd. It details rules, restrictions, disclosure requirements, and penalties related to insider trading and share transactions by company insiders. The content is regulatory and governance-related, focusing on internal rules and compliance for directors and senior management share dealings. It does not contain financial statements, audit opinions, earnings data, or meeting results. It is not a report or announcement of financial results or capital changes. The document fits best under Governance Information (CGR) as it outlines governance practices related to insider shareholding and trading management.
2025-08-25 Chinese
北京双鹭药业股份有限公司2025年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period from January 1, 2025, to June 30, 2025, issued by Beijing Shuanglu Pharmaceutical Co., Ltd. It provides estimated net profit figures and explanations for changes compared to the previous year. The document explicitly states that the forecast is preliminary and that detailed financial data will be disclosed in the company's 2025 half-year report. The document length is short (934 characters) and it is a forward-looking earnings preview rather than a full interim or quarterly report containing actual financial statements. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results or forecasts with key highlights only. H1 2025
2025-07-11 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.